Linking low docosahexaenoic acid intake to Alzheimer’s disease: caution recommended

Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease

“…Ten out of 13 epidemiological studies presented in this review have shown an inverse relationship between n-3 PUFA intake or status and AD pathology. However, postmortem findings have been inconsistent [75] and clinical studies have shown no beneficial effect of n-3 PUFA in patients with AD, except in subgroups of patients with mild AD or MCI. Because epidemiological studies have observed an association between n-3 PUFA and AD, whereas clinical studies have failed to demonstrate a benefit, this suggests that the effect of n-3 PUFA on AD might only be seen after longterm treatment, i.e., lifetime consumption.…”